Compare Neurocrine Biosciences Inc (NBIX) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Shell PLC — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Shell PLC trades at $87.12 (market cap $235.24B). The key difference: Shell PLC is far larger — about 13.5× Neurocrine Biosciences Inc's market cap, and Shell PLC pays a 3.63% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SHEL | |
|---|---|---|
Market Cap | $17.40B | $235.24B |
Sector | Health | Energy |
52-Week High | $180.55 | $94.15 |
52-Week Low | $123.10 | $70.31 |
Enterprise Value | $16.49B | $287.77B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Shell (SHEL) trades at $87.20, showing modest daily decline but maintaining strong technical momentum with bullish moving averages. The stock offers attractive valuation with P/E of 13.43 and P/S of 0.94, supported by solid profitability metrics including 7.01% net margin and 10.64% ROE. Recent Q1 2026 earnings beat expectations at $2.44 EPS versus $2.14 forecast, while the company expands LNG operations in the Caribbean and advances Venezuela gas projects.
Shell presents compelling value with 30% upside to consensus price target of $114.13, supported by 69% analyst buy ratings. However, investors face risks from volatile oil prices, Middle East production disruptions, and declining cash flow trends. The current technical overbought condition suggests potential near-term consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
